



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
11.04.2012 Bulletin 2012/15

(45) Date of publication and mention
of the grant of the patent:
29.02.2012 Bulletin 2012/09

(21) Application number: **01125494.3**

(22) Date of filing: **06.11.2001**

(51) Int Cl.:
C07D 213/75 ^(2006.01) **C07D 215/22** ^(2006.01)
C07D 221/04 ^(2006.01) **C07D 221/16** ^(2006.01)
C07D 401/04 ^(2006.01) **C07D 401/12** ^(2006.01)
C07D 403/12 ^(2006.01) **C07D 405/12** ^(2006.01)
C07D 409/06 ^(2006.01) **C07D 409/12** ^(2006.01)
C07D 409/14 ^(2006.01) **C07D 413/06** ^(2006.01)
C07D 413/12 ^(2006.01) **C07D 417/06** ^(2006.01)
C07D 471/04 ^(2006.01) **A61K 31/505** ^(2006.01)
A61K 31/44 ^(2006.01) **A61K 31/50** ^(2006.01)
A61K 31/4704 ^(2006.01) **A61P 29/00** ^(2006.01)
A61P 35/00 ^(2006.01)

(54) **Carboxylic acid derivatives that inhibit the binding of integrins to their receptors**

Carbonsäurederivate, die die Bindung von Integrinen an ihre Rezeptoren hemmen

Dérivés d'acides carboxyliques inhibant la liaison des intégrines à leurs récepteurs

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

(30) Priority: **06.11.2000 US 707068**
09.10.2001 US 973142

(43) Date of publication of application:
08.05.2002 Bulletin 2002/19

(73) Proprietor: **ENCYSIVE PHARMACEUTICALS, INC.**
New York, NY 10017 (US)

(72) Inventors:
• **Biediger, Ronald J.**
Houston, TX 77095 (US)
• **Chen, Qi**
Pearland, TX 77584 (US)
• **Holland, George W.**
Houston, Texas 77007 (US)
• **Kassir, Jamal M.**
Stafford, Texas 77477 (US)
• **Li, Wen**
Houston, TX 77057 (US)
• **Market, Robert V.**
Pearland, TX 77581 (US)
• **Scott, Ian L.**
Delanson, NY 12053 (US)

• **Wu, Chengde**
Pearland, TX 77584 (US)
• **Decker, Radford E.**
Houston, TX 77018 (US)
• **Li, Jian**
Houston, TX 77382 (US)

(74) Representative: **Weber, Martin et al**
Jones Day
Prinzregentenstraße 11
80538 München (DE)

(56) References cited:
EP-A- 0 355 819 EP-A- 0 512 831
WO-A-00/67746 WO-A-00/68188
WO-A-01/46190 WO-A-91/13862
WO-A-96/22966 WO-A-99/52493
DE-A- 2 614 189 US-A- 5 484 946
US-A- 5 721 366

• **L. ISMAILI ET AL: "Synthesis of New Pyrazolo**
(4,3-c)quinoline-3-one Derivatives and some
Oxazolo(4,5-c)quinoline-2,4-diones" JOURNAL
OF HETEROCYCLIC CHEMISTRY, vol. 36, no. 3,
1999, pages 719-722, XP002298894

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- J.J. PANOUSE ET AL: "Relations structures-activités des immunomodulateurs. Apport de la modélisation moléculaire" ANNALES PHARMACEUTIQUES FRANCAISES, vol. 58, no. 5, 2000, pages 291-302, XP008036024